<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of blastomycosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of blastomycosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of blastomycosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert W Bradsher, Jr, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Blastomycosis is a systemic pyogranulomatous infection, primarily involving the lungs, which arises after inhalation of the conidia of <em>Blastomyces </em>species, including<em> B. dermatitidis, B. gilchristii,</em> and <em>B. helicus</em>. The organism may then disseminate to other sites, especially the skin, but also bone, central nervous system, prostate, and essentially any organ. This topic will focus on <em>B. dermatitidis</em>, the organism for which we have the largest amount of information. The treatment principles for <em>B. dermatitidis</em> can also be applied to other <em>Blastomyces </em>species<em> </em>identified as causing disease in humans </p><p>Treatment approach depends on multiple factors, including severity of disease, site of infection, and degree of immunocompromise in the patient. </p><p>Treatment principles, selection of antifungal therapy, monitoring and duration of therapy, management of refractory disease, and prevention of disease will be reviewed here. </p><p>The mycology, pathogenesis, epidemiology, clinical manifestations, and diagnosis of blastomycosis are discussed separately. (See  <a class="medical medical_review" href="/d/html/2458.html" rel="external">"Mycology, pathogenesis, and epidemiology of blastomycosis"</a> and  <a class="medical medical_review" href="/d/html/2437.html" rel="external">"Clinical manifestations and diagnosis of blastomycosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H2404013538"><span class="h2">Goals of therapy</span><span class="headingEndMark"> — </span>The goals of treatment are to eradicate the infection and prevent progression of disease. We treat all patients diagnosed with blastomycosis, regardless of severity of disease, to prevent disease progression (<a class="graphic graphic_table graphicRef60486" href="/d/graphic/60486.html" rel="external">table 1A</a>) [<a href="#rid1">1-3</a>]. However, some experts may choose to defer therapy in select immunocompetent patients with mild pulmonary disease who are already improving when the diagnosis is established [<a href="#rid4">4</a>]. This approach should only be considered in a patient who has had complete resolution of pneumonia before a respiratory culture returns four to six weeks after initial presentation. In addition, this approach would only be an option if there are no remaining symptoms and after careful inspection looking for skin lesions or other physical examination abnormalities. Laboratory assessment for leukocytosis and abnormal inflammatory markers (C-reactive protein, erythrocyte sedimentation rate) should prompt further investigation for disseminated infection. If therapy is deferred, the patients should be carefully monitored to ensure that the infection resolves. </p><p>Our recommendations for therapy are generally in keeping with the Infectious Diseases Society of America guidelines for the management of blastomycosis [<a href="#rid1">1</a>]. Guidelines for the management of fungal infections, including blastomycosis, have also been published by the American Thoracic Society [<a href="#rid2">2</a>] and the European Confederation of Medical Mycology and International Society for Human and Animal Mycology [<a href="#rid3">3</a>]. </p><p class="headingAnchor" id="H3322217296"><span class="h2">Defining severity of disease</span><span class="headingEndMark"> — </span>Blastomycosis can range from asymptomatic pulmonary infection to severe, life-threatening disease with a high mortality rate. Hematogenous dissemination occurs frequently; extrapulmonary disease of the skin, bones, and genitourinary system is common, but almost any organ can be involved. </p><p>Choice of initial therapy is determined by the severity of disease (<a class="graphic graphic_table graphicRef60486" href="/d/graphic/60486.html" rel="external">table 1A</a>). Distinction of mild, moderate, and severe disease is based on clinical judgment. Generally, immunocompromised patients and those who have evidence of organ failure are classified as having severe disease while the rest are classified as mild to moderate disease. Patients are often already hospitalized for workup of the infection; however, if a patient presents to clinic, hospitalization is warranted for patients with evidence of organ failure, those with central nervous system involvement, and those requiring treatment with amphotericin B. (See <a class="local">'Severe/life-threatening disease without CNS involvement'</a> below and <a class="local">'Mild to moderate disease without CNS involvement'</a> below and <a class="local">'Immunocompromised patients'</a> below.)</p><p class="headingAnchor" id="H641232784"><span class="h2">Antifungal options</span><span class="headingEndMark"> — </span>Amphotericin B and azoles are the mainstay of antifungal therapy for blastomycosis. Echinocandins (eg, <a class="drug drug_general" data-topicid="10141" href="/d/drug information/10141.html" rel="external">micafungin</a>, <a class="drug drug_general" data-topicid="9175" href="/d/drug information/9175.html" rel="external">caspofungin</a>, <a class="drug drug_general" data-topicid="8744" href="/d/drug information/8744.html" rel="external">anidulafungin</a>) should <strong>not</strong> be used for the treatment of blastomycosis due to limited data on efficacy and variable activity in vitro against <em>B. dermatitidis</em> [<a href="#rid5">5,6</a>]. No studies in animal models or human cases have been conducted. </p><p class="headingAnchor" id="H3360378452"><span class="h1">CHOICE OF ANTIFUNGAL THERAPY</span><span class="headingEndMark"> — </span>Treatment options for patients with blastomycosis include amphotericin B or one of the azole drugs (usually <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>) [<a href="#rid1">1,7</a>]. Several factors must be considered when deciding upon the appropriate regimen, such as the organs involved, severity of disease, and the patient’s immune status. </p><p class="headingAnchor" id="H2021199289"><span class="h2">Severe/life-threatening disease without CNS involvement</span></p><p class="headingAnchor" id="H618347774"><span class="h3">Initial therapy with amphotericin B</span><span class="headingEndMark"> — </span>For patients with life-threatening or severe blastomycosis without CNS involvement, we suggest initiating therapy with a lipid formulation of amphotericin B (3 to 5 mg/kg intravenously [IV] once daily) (<a class="graphic graphic_table graphicRef60486 graphicRef140275" href="/d/graphic/60486.html" rel="external">table 1A-B</a>) [<a href="#rid1">1</a>]. If lipid formulations of amphotericin B are not available, <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> (0.7 to 1.0 mg/kg IV once daily) is an alternative option. We continue amphotericin B therapy until the patient shows signs of clinical improvement, typically after one or two weeks of therapy. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>− Amphotericin B therapy is frequently complicated by significant toxicity, including infusion reactions, nephrotoxicity, and electrolyte abnormalities. Lipid formulations of amphotericin B (<a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> [AmBisome] and <a class="drug drug_general" data-topicid="8724" href="/d/drug information/8724.html" rel="external">amphotericin B lipid complex</a> [Abelcet]) are generally better tolerated than <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a>, but toxicities can occur with any formulation. (See  <a class="medical medical_review" href="/d/html/476.html" rel="external">"Pharmacology of amphotericin B", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1">Renal function and electrolyte levels (including magnesium) should be monitored closely during treatment; need for potassium and magnesium replenishment is common. A sharp, steady decline in kidney function while on therapy should prompt attention, as acute kidney injury is the most common reason for interruption or premature termination of therapy. The dose of amphotericin B may need to be reduced or held for a day or two. (See  <a class="medical medical_review" href="/d/html/2364.html" rel="external">"Amphotericin B nephrotoxicity"</a>.) </p><p></p><p class="bulletIndent1">For patients who develop nonanaphylactic, immediate infusion-related reactions (eg, fever, chills, rigors, nausea, or vomiting), premedication with a nonsteroidal anti-inflammatory agent, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, antihistamines, and/or <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> can be administered to help reduce symptoms. (See  <a class="medical medical_review" href="/d/html/476.html" rel="external">"Pharmacology of amphotericin B", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> − The evidence regarding the use of amphotericin B [<a href="#rid8">8-11</a>] for the treatment of blastomycosis comes from small observational studies in which only a subset of patients had disseminated disease. When administered in cumulative doses greater than 1 g, IV <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> has been reported to result in cure without relapse in 77 to 91 percent of patients with blastomycosis [<a href="#rid9">9</a>]. A review of 326 blastomycosis cases over a 10-year period noted a cure rate of 86 percent and a relapse rate of only 4 percent for amphotericin B deoxycholate-treated patients [<a href="#rid10">10</a>]. Relapse rates appear to be dose dependent [<a href="#rid8">8,11</a>]. In one series, for example, relapse occurred in 1 of 28 patients who received more than 1.5 g of amphotericin B deoxycholate compared with 6 of 21 patients who received less than 1.5 g [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">Amphotericin B deoxycholate</a> is the agent that has been used most frequently for the treatment of blastomycosis [<a href="#rid8">8</a>]. Lipid formulations of amphotericin B are effective in animal models of blastomycosis [<a href="#rid12">12</a>] but have not been studied in clinical trials [<a href="#rid1">1</a>]. Despite this limitation, a lipid formulation is generally recommended for the treatment of blastomycosis when amphotericin B is indicated, because lipid formulations have been used extensively and are generally considered to be as effective as amphotericin B deoxycholate [<a href="#rid13">13-16</a>] while being less nephrotoxic and having fewer infusional toxicities [<a href="#rid1">1</a>]. </p><p></p><p class="headingAnchor" id="H154116172"><span class="h3">Step-down azole therapy</span><span class="headingEndMark"> — </span>Once improvement is noted (usually after one to two weeks), we switch therapy to <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> (200 mg orally three times daily for three days, then 200 mg twice daily). Several formulations of itraconazole are available. We generally continue treatment for 6 to 12 months, depending on clinical response and other host factors (<a class="graphic graphic_table graphicRef60486 graphicRef140275" href="/d/graphic/60486.html" rel="external">table 1A-B</a>). (See <a class="local">'Duration of therapy'</a> below.)</p><p>Details on <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> administration (eg, dosing, formulations) and efficacy are discussed elsewhere. (See <a class="local">'Itraconazole'</a> below.)</p><p>If <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> cannot be used, other step-down azole alternatives include <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a>, <a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">isavuconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>, or <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>. (See <a class="local">'Alternatives to itraconazole'</a> below.) </p><p class="headingAnchor" id="H1541858863"><span class="h3">Adjunctive therapies</span><span class="headingEndMark"> — </span>Rarely, patients can present with fulminant pneumonia and adult respiratory distress syndrome (ARDS) [<a href="#rid17">17,18</a>]. Such patients have a mortality rate as high as 50 to 89 percent, and death usually occurs within the first few days of hospitalization [<a href="#rid17">17</a>]. Treatment with glucocorticoids has been used adjunctively in some patients with ARDS due to blastomycosis [<a href="#rid1">1,19,20</a>]. There have not been, and likely will never be, clinical trials to assess whether glucocorticoids are beneficial in reducing the inflammatory response associated with blastomycosis. Thus, steroids should only be administered in patients who are intubated, have ARDS, and meet the ARDS criteria for glucocorticoid initiation. (See  <a class="medical medical_review" href="/d/html/1641.html" rel="external">"Acute respiratory distress syndrome: Fluid management, pharmacotherapy, and supportive care in adults", section on 'Glucocorticoids'</a>.) </p><p>Case reports have also described the use of extracorporeal membrane oxygenation as a supportive measure in this setting [<a href="#rid21">21-23</a>]. </p><p class="headingAnchor" id="H1580783434"><span class="h2">Mild to moderate disease without CNS involvement</span></p><p class="headingAnchor" id="H3308806813"><span class="h3">Itraconazole</span><span class="headingEndMark"> — </span>For patients with mild to moderate blastomycosis and no CNS involvement, we suggest treating with oral <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> for 6 to 12 months (<a class="graphic graphic_table graphicRef60486 graphicRef140275" href="/d/graphic/60486.html" rel="external">table 1A-B</a>) [<a href="#rid1">1</a>]. We prefer itraconazole over other azoles because there are more clinical data supporting its efficacy in treatment of blastomycosis compared with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a>, and <a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">isavuconazole</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and choice of formulation </strong>− There are important pharmacokinetic differences between the capsules and liquid preparations of <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>. We prefer starting with itraconazole capsules (200 mg three times daily for three days, then 200 mg twice a day) because this formulation has the most robust efficacy data in treatment of blastomycosis. However, absorption can be problematic; if serum drug concentration levels (discussed in detail below) are not adequate, or if the patient requires a medication that blocks gastric acid secretion (eg, proton pump inhibitor), we typically use the liquid formulation (200 mg three times daily for three days, then once or twice daily) or the Super-BioAvailable (SUBA) itraconazole capsule (130 mg three times daily for three days, then 130 mg once daily) [<a href="#rid24">24</a>] because of their improved absorption compared with the original capsule formulation (<a class="graphic graphic_table graphicRef140275" href="/d/graphic/140275.html" rel="external">table 1B</a>). </p><p></p><p class="bulletIndent1">The oral capsules should be taken with a fatty meal and many clinicians also suggest a carbonated beverage (eg, Coca-Cola) be added. The liquid formulation should be taken on an empty stomach. When using <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>, serum concentration levels should be obtained after two weeks of therapy to ensure adequate blood levels. (See <a class="local">'Therapeutic drug monitoring'</a> below.)</p><p></p><p class="bulletIndent1">The absorption of the original <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> capsule formulation is highly variable and requires gastric acidity. In patients who must continue to receive concomitant medications that decrease gastric acidity (eg, proton pump inhibitors), drug concentration levels in the blood are reduced and may not reach therapeutic levels. In contrast, the liquid formulation has better bioavailability, does not require an acidic environment, and is taken on an empty stomach. </p><p></p><p class="bulletIndent1">SUBA <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> is a capsule formulation that has better absorption from the gastrointestinal tract with reportedly better blood levels than the original capsule. In the United States, the US Food and Drug Administration has approved it for treatment of endemic mycoses, including blastomycosis, although there are minimal data published regarding its use in this infection. A clinical trial comparing SUBA itraconazole with conventional itraconazole for endemic mycoses, including blastomycosis, is ongoing. (See  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Pharmacokinetics'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> − <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">Itraconazole</a> is generally well tolerated. In a nonrandomized open-label study of 48 patients with blastomycosis, treatment was discontinued in only 1 of 48 treated patients because of drug toxicity [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1">Patients taking <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> may experience gastrointestinal symptoms, such as nausea, vomiting, and abdominal pain. This can often lead to poor adherence. Other side effects include the triad of hypokalemia, peripheral edema, and hypertension, as well as hepatotoxicity, which can occur with all azoles. Heart failure has been reported, and there is a boxed warning that itraconazole should not be used in patients who are known to have congestive heart failure. Very rarely, itraconazole (and <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a>) can cause pseudohyperaldosteronism with severe hypokalemia, hypertension, and metabolic alkalosis. Itraconazole solution is reported to have a bad taste and can cause diarrhea. We generally check aminotransferases at the initiation of itraconazole, one month into therapy, and, if normal, then every two months thereafter. (See  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Itraconazole'</a>.)</p><p></p><p>If hypertension, heart failure, or pretibial edema is discovered, serum concentrations should be obtained and dose lowered if levels are elevated above 5 mcg/mL. If these adverse effects are seen in patients with serum concentrations within the preferred range, the drug must be stopped. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> − The evidence regarding the use of <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> [<a href="#rid25">25-27</a>] for the treatment of blastomycosis comes from small observational studies. As an example, in a nonrandomized open-label study of 48 patients with blastomycosis, a daily dose of 200 to 400 mg itraconazole was 90 percent effective [<a href="#rid25">25</a>]. In a separate study, 39 of 42 were cured with itraconazole therapy, although two required a second course of itraconazole due to relapse [<a href="#rid27">27</a>]. Of the three who failed itraconazole therapy, 1 failed initial therapy and two had relapses that required amphotericin B therapy. </p><p></p><p class="headingAnchor" id="H548429111"><span class="h3">Alternatives to itraconazole</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">Posaconazole</a>, <a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">isavuconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>, or <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> can be used as alternatives in patients who are unable to take <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> [<a href="#rid1">1</a>]. When itraconazole cannot be used, we prefer using oral posaconazole delayed-release capsules as an alternative option due to its tolerability and similar molecular structure to itraconazole. </p><p>The use of <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> or <a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">isavuconazole</a> has been reported in only a few cases of blastomycosis in humans [<a href="#rid28">28-31</a>]. <em>B. dermatitidis</em> is susceptible to posaconazole, and this agent has proven effective in murine models of blastomycosis [<a href="#rid32">32</a>]. <em>B. dermatitidis</em> is also susceptible to isavuconazole. Isavuconazole may be preferred in certain settings (eg, organ transplant recipients) because it is the only azole that does not prolong the QTc interval and it has a reduced risk of drug-drug interactions [<a href="#rid31">31</a>].</p><p><a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">Voriconazole</a> and <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> are discussed in detail elsewhere. (See <a class="local">'Voriconazole as preferred agent'</a> below and <a class="local">'Alternatives to voriconazole'</a> below.)</p><p><a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">Ketoconazole</a> is not recommended any longer for blastomycosis because of serious adverse effects and a higher relapse rate than <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> [<a href="#rid33">33-35</a>].</p><p class="headingAnchor" id="H328570771"><span class="h2">Central nervous system disease</span></p><p class="headingAnchor" id="H2413502550"><span class="h3">Initial therapy with amphotericin B</span><span class="headingEndMark"> — </span>For patients with CNS involvement, we suggest a lipid formulation of amphotericin B (5 mg/kg per day) for four to six weeks followed by an oral azole for at least 12 months (<a class="graphic graphic_table graphicRef60486 graphicRef140275" href="/d/graphic/60486.html" rel="external">table 1A-B</a>) [<a href="#rid1">1</a>]. If lipid formulations of amphotericin B are not available, <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> (1.0 mg/kg IV once daily) is an alternative option. We prefer the lipid formulations of amphotericin B over the conventional formulation because they are less toxic and liposomal amphotericin has better CNS penetration. The recommendations for treatment of CNS blastomycosis are based upon case series and small observational studies [<a href="#rid15">15,16,36,37</a>]. </p><p class="headingAnchor" id="H2130892363"><span class="h3">Step-down therapy</span><span class="headingEndMark"> — </span>It is not clear which azole is optimal for step-down therapy for CNS blastomycosis. Based upon the limited data available, our choice of azole in order of preference is <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>, and <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>. </p><p class="headingAnchor" id="H547419197"><span class="h4">Voriconazole as preferred agent</span><span class="headingEndMark"> — </span>For patients with CNS blastomycosis, we suggest <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> (200 to 400 mg twice daily) as the preferred azole agent (<a class="graphic graphic_table graphicRef60486 graphicRef140275" href="/d/graphic/60486.html" rel="external">table 1A-B</a>) [<a href="#rid36">36</a>]. Voriconazole has good CNS and cerebrospinal fluid (CSF) penetration [<a href="#rid38">38</a>] and excellent activity against <em>B. dermatitidis</em> [<a href="#rid39">39,40</a>]. Although no clinical trials have been performed comparing oral azole regimens for step-down therapy of CNS blastomycosis, voriconazole has been demonstrated to be an effective treatment for CNS blastomycosis in case reports and small retrospective studies [<a href="#rid15">15,36,41,42</a>]. In a multicenter review of 22 CNS blastomycosis cases, eight patients received an amphotericin B formulation followed by voriconazole; all but one patient had a favorable outcome [<a href="#rid36">36</a>].</p><p>In addition to hepatotoxicity, which is a known adverse effect of all azoles, <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> is also associated with other adverse effects, such as vision changes, visual and/or auditory hallucinations, myoclonic movements, confusion, agitation, alopecia, nail changes, bone pain due to periostitis, rashes, and QTc prolongation. Patients taking voriconazole should be counseled on the possibility of these adverse effects and asked at each visit about any vision abnormalities, any hallucinatory or other neurologic symptoms, and skin and soft tissue symptoms. We generally check aminotransferases at the initiation of therapy and monthly thereafter. We obtain an electrocardiogram (EKG) to evaluate baseline QTc prior to treatment initiation and do not repeat an EKG unless the patient initiates other QTc-prolonging drugs. </p><p>Many of these adverse effects are dose-dependent and increase with higher trough levels. Because <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> exhibits nonlinear pharmacokinetics resulting in inter- and intrapatient variability in serum concentrations, monitoring trough concentrations should be performed in patients receiving voriconazole. This is discussed in detail separately. (See <a class="local">'Therapeutic drug monitoring'</a> below and  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Serum drug concentration monitoring'</a>.)</p><p class="headingAnchor" id="H2385897575"><span class="h4">Alternatives to voriconazole</span><span class="headingEndMark"> — </span>For patients with CNS blastomycosis in whom <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> cannot be used, we favor <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> above other azole agents. High-dose <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> is also an option, but in our experience, we have seen more failures with fluconazole compared with itraconazole. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Itraconazole</strong> − For patients with CNS blastomycosis in whom <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> cannot be used, we use <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> (200 mg three times daily for three days followed by 200 mg two to three times daily) (<a class="graphic graphic_table graphicRef140275" href="/d/graphic/140275.html" rel="external">table 1B</a>). Itraconazole has poor CSF penetration but has greater activity against <em>B. dermatitidis </em>than <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> [<a href="#rid1">1</a>]. There are a few case reports of success with itraconazole for the therapy of CNS blastomycosis [<a href="#rid43">43,44</a>]. Details of administration of itraconazole are discussed elsewhere. (See <a class="local">'Itraconazole'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluconazole</strong> − For patients with CNS blastomycosis in whom neither <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> nor <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> can be used, high-dose <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> (800 mg once daily) is an option due to its excellent CNS and CSF penetration. Drug interactions are less pronounced than those reported for itraconazole, and fluconazole is well absorbed in achlorhydric patients and in those treated with H2 blockers. However, it has less activity against <em>B. dermatitidis </em>than the other azoles [<a href="#rid45">45</a>]. </p><p></p><p class="bulletIndent1">Only a few patients with CNS blastomycosis have been treated with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>. Although there are anecdotal reports of successful treatment of CNS blastomycosis with fluconazole [<a href="#rid36">36,46,47</a>], the data in patients without CNS involvement suggest that fluconazole is not as effective as <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> in the treatment of blastomycosis. The results of a small pilot study in patients who did not have CNS blastomycosis employing lower-dose fluconazole were disappointing, with a successful outcome noted in only 65 percent of the 23 patients treated with daily doses of 200 mg and 400 mg [<a href="#rid48">48</a>]. In a second study reporting treatment of 39 patients with daily doses of 400 mg and 800 mg, a successful outcome was noted in 87 percent [<a href="#rid49">49</a>]. </p><p></p><p class="headingAnchor" id="H1661348830"><span class="h2">Special populations</span></p><p class="headingAnchor" id="H2091495386"><span class="h3">Immunocompromised patients</span><span class="headingEndMark"> — </span>For immunocompromised patients (eg, advanced human immunodeficiency virus [HIV], solid organ transplant recipients) with blastomycosis, we start treatment with a lipid formulation of amphotericin B regardless of severity of disease (<a class="graphic graphic_table graphicRef60486 graphicRef140275" href="/d/graphic/60486.html" rel="external">table 1A-B</a>), because of the higher morbidity and mortality and higher relapse rates in this patient population [<a href="#rid50">50-52</a>]. If lipid formulations of amphotericin B are not available, <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> is an alternative. We prefer a lipid formulation of amphotericin B to avoid the nephrotoxicity of amphotericin B deoxycholate. Details of administration of amphotericin B are discussed elsewhere. (See <a class="local">'Initial therapy with amphotericin B'</a> above.)</p><p>Once clinical improvement in observed (generally after one to two weeks of amphotericin B therapy), we transition immunocompromised patients without CNS disease to <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> therapy. In patients with CNS disease, we continue <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> for four to six weeks and then transition to <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>. Patients not tolerant to the initial azole agent can be switched to another azole for the remainder of treatment duration but should be monitored closely for symptom worsening or relapse (<a class="graphic graphic_table graphicRef60486 graphicRef140275" href="/d/graphic/60486.html" rel="external">table 1A-B</a>). Details of administration of these azole agents are discussed elsewhere. (See <a class="local">'Itraconazole'</a> above and <a class="local">'Voriconazole as preferred agent'</a> above and <a class="local">'Alternatives to itraconazole'</a> above.)</p><p>Immunocompromised patients with blastomycosis are more likely to present with severe pulmonary or disseminated infection, especially to the CNS, and to have a fatal outcome [<a href="#rid1">1,50,51</a>]. The recommendations for treatment of blastomycosis in immunocompromised hosts are based upon case reports and small case series [<a href="#rid14">14,50,51,53-57</a>]. </p><p class="headingAnchor" id="H870030822"><span class="h3">Pregnant females</span><span class="headingEndMark"> — </span>In pregnant females with blastomycosis, we administer a lipid formulation of amphotericin B (3 to 5 mg/kg IV once daily) (<a class="graphic graphic_table graphicRef60486 graphicRef140275" href="/d/graphic/60486.html" rel="external">table 1A-B</a>) [<a href="#rid1">1</a>] for the duration of treatment while pregnant, regardless of disease severity. Azoles have embryotoxic and teratogenic properties and are therefore contraindicated in pregnancy. </p><p class="headingAnchor" id="H4071207808"><span class="h3">Children</span><span class="headingEndMark"> — </span>We approach the choice of antifungal therapy in children similar to that in adults, with the exception of neonates who should receive <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> (1 mg/kg IV once daily) for the duration of therapy, regardless of disease severity (<a class="graphic graphic_table graphicRef60486 graphicRef140275" href="/d/graphic/60486.html" rel="external">table 1A-B</a>) [<a href="#rid1">1</a>]. In general, children tolerate the deoxycholate formulation of amphotericin B better than adults, and we do not have a preference between the different formulations of amphotericin B in the treatment of blastomycosis in children. The approach to treatment in immunocompromised children is similar to that of immunocompromised adults. </p><p>The treatment of blastomycosis in children is based upon case reports and small case series [<a href="#rid15">15,56,58,59</a>]. Blastomycosis occurs less commonly in children; however, the clinical spectrum of disease and therapeutic considerations are similar to adults [<a href="#rid58">58</a>]. </p><p class="headingAnchor" id="H3075380681"><span class="h1">MONITORING AND TREATMENT DURATION</span></p><p class="headingAnchor" id="H3239111914"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>Patients with blastomycosis should be monitored closely, especially in the first few months of therapy. For azole antifungals, therapeutic drug monitoring is recommended. Monitoring for medication adherence, adverse effects, and clinical response is necessary to ensure treatment response and to detect treatment failure and relapses early. </p><p class="headingAnchor" id="H1185479584"><span class="h3">Therapeutic drug monitoring</span><span class="headingEndMark"> — </span>We suggest therapeutic drug monitoring for <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>, and <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> at the beginning of therapy, when there is a concern for inadequate serum drug concentrations (eg, lack of clinical improvement), or when other drugs that could have drug-drug interactions have been added to the patient’s therapeutic regimen (see <a class="local">'Approach to patients with treatment failure'</a> below). This is discussed further elsewhere. (See  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Serum drug concentration monitoring'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Itraconazole</strong> − The serum <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> concentration should be measured after at least two weeks of therapy to ensure adequate levels [<a href="#rid1">1</a>]. Serum concentrations can be measured at any time since steady state has already been achieved. Serum concentrations depend on the type of assay used. High-performance liquid chromatography (HPLC) assays report the hydroxyitraconazole and itraconazole concentrations and these two should be added together to obtain the final serum concentration. Thus, when using an HPLC assay, serum concentrations (itraconazole plus the hydroxyitraconazole metabolite) greater than 1 to 2 mcg/mL and less than 5 mcg/mL are preferred [<a href="#rid60">60</a>]. In contrast, when using a bioassay, which does not separate out the two forms of itraconazole, a serum level greater than 3 mcg/mL is preferred. (See  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Itraconazole'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Voriconazole</strong> – The serum trough <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> concentration should be measured four to seven days into therapy. Trough levels should be obtained within an hour of the next scheduled voriconazole dose. A target goal is a trough concentration between 1 mcg/mL and 5.5 mcg/mL, although some experts prefer a minimum serum concentration of 2 mcg/mL. Trough concentrations below 1 mcg/mL and above 5.5 mcg/mL warrant an increase and decrease, respectively, in voriconazole dose to optimize therapeutic effect and minimize adverse effects. (See  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Voriconazole'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Posaconazole</strong> – The serum <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> concentration should be measured four to seven days into therapy. Trough levels should be obtained within an hour of the next scheduled posaconazole dose. A trough concentration ≥1 mcg/mL is preferred. (See  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Posaconazole'</a>.)</p><p></p><p class="headingAnchor" id="H3836391259"><span class="h3">Monitoring for clinical response</span><span class="headingEndMark"> — </span>After initiation of therapy, patients should be followed closely for clinical improvement (eg, symptoms, radiographic features). In general, patients show signs of clinical improvement within the first two weeks of therapy. Lack of any clinical improvement after two weeks of therapy is concerning for treatment failure. In patients with central nervous system (CNS) involvement, lack of clinical improvement after four to six weeks should prompt goals of care discussion given the poor prognosis. (See <a class="local">'Approach to patients with treatment failure'</a> below.)</p><p>Monitoring generally entails repeated assessments of the patient’s clinical signs and symptoms and radiographic findings. In some situations (eg, pulmonary blastomycosis), repeating cultures may be reasonable. Although urine antigen levels for blastomycosis appear to decline with successful treatment and increase with recurrence of illness, data are limited to guide use of antigen testing in monitoring of patients on treatment [<a href="#rid61">61,62</a>]. </p><p class="headingAnchor" id="H3544385881"><span class="h2">Duration of therapy</span><span class="headingEndMark"> — </span>We treat most patients with blastomycosis for 6 to 12 months (<a class="graphic graphic_table graphicRef60486" href="/d/graphic/60486.html" rel="external">table 1A</a>); treatment should generally extend several months beyond the time of resolution of clinical symptoms and radiographic findings [<a href="#rid1">1</a>]. For example, for patients presenting with skin lesions, we typically treat for six additional months after the skin lesions have resolved. For patients with bone or CNS disease or who are immunocompromised, we continue therapy for at least 12 months because of the higher risk of relapse in these cases [<a href="#rid1">1,63</a>]. Children with severe or life-threatening blastomycosis also warrant at least 12 months of therapy. </p><p class="headingAnchor" id="H2519342533"><span class="h1">APPROACH TO PATIENTS WITH TREATMENT FAILURE</span><span class="headingEndMark"> — </span>Treatment failure should be suspected when there is minimal to no improvement in symptoms after two to three weeks of therapy or initial improvement has stalled and symptoms persist after three to six months of therapy. </p><p>Reasons for treatment failure include subtherapeutic serum drug levels, poor adherence to medications (often due to drug intolerance), or poor host immune response. Relapse of infection after a patient has completed treatment is more common in immunocompromised patients [<a href="#rid50">50-52</a>] and in those who received alternative antifungal options during their treatment course (eg, <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>) [<a href="#rid10">10,34,35</a>]. </p><p>In patients with suspected treatment failure, every effort should be made to establish evidence of ongoing infection, either by a positive culture or histopathology. In cases of suspected treatment failure where obtaining repeat culture or tissue specimen is not feasible, urinary antigen testing may be helpful. Urinary antigen testing has suboptimal specificity, but high sensitivity, for detection of blastomycosis. We assess whether the patient is receiving therapeutic drug doses by evaluating for nonadherence and checking drug levels. If drug levels are subtherapeutic, we adjust the dose to target therapeutic levels and re-evaluate several days to a week later. Immune status should be optimized in immunosuppressed patients by making sure patients with HIV are on effective antiretroviral therapy and stopping or reducing doses of immunosuppressive agents when possible. </p><p>Patients who experience treatment failure or relapse should be managed in consultation with an infectious diseases provider experienced in the treatment of blastomycosis.</p><p class="headingAnchor" id="H2141145291"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Prevention of blastomycosis primarily consists of secondary prevention, as avoiding exposure in endemic areas is difficult and there are no data to suggest benefit of primary prophylaxis. </p><p class="headingAnchor" id="H993072783"><span class="h2">Avoiding exposure</span><span class="headingEndMark"> — </span>Avoidance of exposure is difficult as the fungus is ubiquitous in the environment in endemic areas. Waterways, animal waste substrates, and wood byproducts have all been associated with <em>Blastomyces</em> spp or blastomycosis outbreaks. For patients at increased risk of blastomycosis (eg, severely immunocompromised individuals such as transplant patients or those with acquired immunodeficiency syndrome [AIDS]) living in areas endemic for blastomycosis, we educate them on avoiding activities involving disruption of soil and vegetation (eg, forestry work, hunting, camping) but also acknowledge that it is very difficult to eradicate risk completely. </p><p class="headingAnchor" id="H1686863182"><span class="h2">Secondary prophylaxis</span><span class="headingEndMark"> — </span>Relapses are common in patients in whom immunosuppression cannot be reversed [<a href="#rid50">50-52</a>]. As a result, we suggest long-term suppressive therapy with <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> for immunocompromised patients while they remain immunocompromised and for patients with HIV and a CD4 count of ≤150 cells/microL [<a href="#rid1">1</a>]. We generally check an itraconazole level after two to three months of therapy. Further levels can be considered if there are concerns for toxicity or lack of adherence. Patients with HIV receiving antiretroviral therapy who have had a CD4 cell count of &gt;150 cells/microL for at least six months can discontinue itraconazole therapy for blastomycosis after a minimum of one year [<a href="#rid1">1</a>]. This recommendation is derived from data in patients with HIV and histoplasmosis demonstrating that it is safe to discontinue itraconazole under these circumstances [<a href="#rid64">64</a>]. No data are available for the discontinuation of secondary prophylaxis in other immunocompromised states (eg, transplant recipients). </p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overall approach to treatment</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Blastomycosis is a systemic pyogranulomatous illness, infecting the lungs, which arises after inhalation of the conidia of <em>Blastomyces </em>species. The infection has the potential to disseminate to skin, bone, prostate, and other organs. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The goals of treatment are to eradicate the infection and prevent progression of disease. We treat all patients diagnosed with blastomycosis, regardless of severity of disease, to prevent disease progression. (See <a class="local">'Goals of therapy'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with severe disease include immunocompromised patients, those with organ failure, and are usually hospitalized. Patients with mild to moderate symptoms generally can be managed as outpatients. (See <a class="local">'Defining severity of disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of antifungal therapy</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe/life-threatening disease without CNS involvement</strong> − For immunocompetent patients with life-threatening or severe blastomycosis (eg, hospitalized patients) and no central nervous system (CNS) involvement, we suggest initiating therapy with a lipid formulation of amphotericin B rather than oral antifungal therapy (<a class="graphic graphic_table graphicRef60486 graphicRef140275" href="/d/graphic/60486.html" rel="external">table 1A-B</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Once the patient clinically improves, we suggest switching to <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> rather than another oral antifungal agent or continuing therapy with amphotericin B (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Severe/life-threatening disease without CNS involvement'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild and moderate disease without CNS involvement </strong>– For immunocompetent patients with mild or moderate blastomycosis who do not warrant hospitalization and have no CNS involvement, we suggest initiating treatment with <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> rather than another oral antifungal agent or amphotericin B (<a class="graphic graphic_table graphicRef60486 graphicRef140275" href="/d/graphic/60486.html" rel="external">table 1A-B</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Mild to moderate disease without CNS involvement'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CNS disease</strong> − For patients with CNS involvement, we suggest initiating treatment with a lipid formulation of amphotericin B rather than an oral antifungal agent (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Following initial amphotericin B therapy, we suggest transitioning to <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>) rather than another oral antifungal agent or amphotericin B (<a class="graphic graphic_table graphicRef60486 graphicRef140275" href="/d/graphic/60486.html" rel="external">table 1A-B</a>). If there is no clinical improvement after four to six weeks, prognosis is poor and goals of care should be discussed. (See <a class="local">'Central nervous system disease'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Special populations</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For immunocompromised patients, regardless of disease severity, we suggest initiating therapy with amphotericin B rather than an oral azole agent (<a class="graphic graphic_table graphicRef60486 graphicRef140275" href="/d/graphic/60486.html" rel="external">table 1A-B</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We transition to azole therapy once they are clinically improving. (See <a class="local">'Immunocompromised patients'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Pregnant females with blastomycosis should remain on amphotericin B for the duration of treatment while pregnant due to azole agents’ embryogenic and teratogenic effects (<a class="graphic graphic_table graphicRef60486 graphicRef140275" href="/d/graphic/60486.html" rel="external">table 1A-B</a>). (See <a class="local">'Pregnant females'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Therapeutic drug monitoring</strong> – Serum trough levels of <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> or <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> should be checked after four to seven days of therapy (goal trough level: 1 to 5.5 mcg/mL and &gt;1 mcg/mL, respectively). Serum levels of <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> should be checked after two weeks of therapy (goal level: 1 to 2 mcg/mL). (See <a class="local">'Therapeutic drug monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of therapy </strong>– For patients with severe or life-threatening blastomycosis or with immunocompromising conditions, we generally administer amphotericin B for one to two weeks or until there is clinical improvement. For patients with CNS disease, we generally administer amphotericin B for four to six weeks. Duration of oral azole therapy is typically 6 to 12 months (<a class="graphic graphic_table graphicRef60486" href="/d/graphic/60486.html" rel="external">table 1A</a>). Details on duration of oral azole therapy for specific patient populations and disease severity are discussed in detail above. (See <a class="local">'Duration of therapy'</a> above and <a class="local">'Special populations'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary prophylaxis</strong> – For immunocompromised patients, such as patients with HIV and CD4 count ≤150 cells/microL, we suggest long-term suppressive therapy with <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Patients with HIV receiving antiretroviral therapy who have had a CD4 cell count of &gt;150 cells/microL for at least six months can discontinue itraconazole therapy after a minimum of one year of treatment. (See <a class="local">'Prevention'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:1801.</a></li><li><a class="nounderline abstract_t">Limper AH, Knox KS, Sarosi GA, et al. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011; 183:96.</a></li><li><a class="nounderline abstract_t">Thompson GR 3rd, Le T, Chindamporn A, et al. Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology. Lancet Infect Dis 2021; 21:e364.</a></li><li><a class="nounderline abstract_t">Sarosi GA, Davies SF, Phillips JR. Self-limited blastomycosis: a report of 39 cases. Semin Respir Infect 1986; 1:40.</a></li><li><a class="nounderline abstract_t">Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36:2950.</a></li><li><a class="nounderline abstract_t">Zhanel GG, Karlowsky JA, Harding GA, et al. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother 1997; 41:863.</a></li><li><a class="nounderline abstract_t">Dukik K, Al-Hatmi AMS, Curfs-Breuker I, et al. Antifungal Susceptibility of Emerging Dimorphic Pathogens in the Family Ajellomycetaceae. Antimicrob Agents Chemother 2018; 62.</a></li><li><a class="nounderline abstract_t">Parker JD, Doto IL, Tosh FE. A decade of experience with blastomycosis and its treatment with amphotericin B. A National Communicable Disease Center Cooperative Mycoses Study. Am Rev Respir Dis 1969; 99:895.</a></li><li><a class="nounderline abstract_t">Bradsher RW. Histoplasmosis and blastomycosis. Clin Infect Dis 1996; 22 Suppl 2:S102.</a></li><li><a class="nounderline abstract_t">Chapman SW, Lin AC, Hendricks KA, et al. Endemic blastomycosis in Mississippi: epidemiological and clinical studies. Semin Respir Infect 1997; 12:219.</a></li><li><a class="nounderline abstract_t">Abernathy RS. Amphotericin therapy of North American blastomycosis. Antimicrob Agents Chemother (Bethesda) 1966; 6:208.</a></li><li><a class="nounderline abstract_t">Clemons KV, Stevens DA. Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis. Antimicrob Agents Chemother 1991; 35:2144.</a></li><li><a class="nounderline abstract_t">Cook PP. Amphotericin B lipid complex for the treatment of recurrent blastomycosis of the brain in a patient previously treated with itraconazole. South Med J 2001; 94:548.</a></li><li><a class="nounderline abstract_t">Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 2005; 40 Suppl 6:S401.</a></li><li><a class="nounderline abstract_t">Panicker J, Walsh T, Kamani N. Recurrent central nervous system blastomycosis in an immunocompetent child treated successfully with sequential liposomal amphotericin B and voriconazole. Pediatr Infect Dis J 2006; 25:377.</a></li><li><a class="nounderline abstract_t">Chowfin A, Tight R, Mitchell S. Recurrent blastomycosis of the central nervous system: case report and review. Clin Infect Dis 2000; 30:969.</a></li><li><a class="nounderline abstract_t">Meyer KC, McManus EJ, Maki DG. Overwhelming pulmonary blastomycosis associated with the adult respiratory distress syndrome. N Engl J Med 1993; 329:1231.</a></li><li><a class="nounderline abstract_t">Lemos LB, Baliga M, Guo M. Acute respiratory distress syndrome and blastomycosis: presentation of nine cases and review of the literature. Ann Diagn Pathol 2001; 5:1.</a></li><li><a class="nounderline abstract_t">Lahm T, Neese S, Thornburg AT, et al. Corticosteroids for blastomycosis-induced ARDS: a report of two patients and review of the literature. Chest 2008; 133:1478.</a></li><li><a class="nounderline abstract_t">Schwartz IS, Embil JM, Sharma A, et al. Management and Outcomes of Acute Respiratory Distress Syndrome Caused by Blastomycosis: A Retrospective Case Series. Medicine (Baltimore) 2016; 95:e3538.</a></li><li><a class="nounderline abstract_t">Zhao Y, Seelhammer TG, Barreto EF, Wilson JW. Altered Pharmacokinetics and Dosing of Liposomal Amphotericin B and Isavuconazole during Extracorporeal Membrane Oxygenation. Pharmacotherapy 2020; 40:89.</a></li><li><a class="nounderline abstract_t">Servais R, Ammar MA, Gurnani PK. Treatment of pulmonary blastomycosis with high-dose liposomal amphotericin B in a patient receiving extracorporeal membrane oxygenation. BMJ Case Rep 2019; 12.</a></li><li><a class="nounderline abstract_t">Branick K, Taylor MJ, Trump MW, Wall GC. Apparent interference with extracorporeal membrane oxygenation by liposomal amphotericin B in a patient with disseminated blastomycosis receiving continuous renal replacement therapy. Am J Health Syst Pharm 2019; 76:810.</a></li><li><a class="nounderline abstract_t">Thompson GR 3rd, Lewis P, Mudge S, et al. Open-Label Crossover Oral Bioequivalence Pharmacokinetics Comparison for a 3-Day Loading Dose Regimen and 15-Day Steady-State Administration of SUBA-Itraconazole and Conventional Itraconazole Capsules in Healthy Adults. Antimicrob Agents Chemother 2020; 64.</a></li><li><a class="nounderline abstract_t">Dismukes WE, Bradsher RW Jr, Cloud GC, et al. Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med 1992; 93:489.</a></li><li><a class="nounderline abstract_t">Bradsher RW. Blastomycosis. Clin Infect Dis 1992; 14 Suppl 1:S82.</a></li><li class="breakAll">Bradsher RW. Intraconazole therapy of blastomycosis: cure following progression or relapse after ketoconazole [abstract no. 1351]. In: Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1987.</li><li><a class="nounderline abstract_t">Proia LA, Harnisch DO. Successful use of posaconazole for treatment of blastomycosis. Antimicrob Agents Chemother 2012; 56:4029.</a></li><li><a class="nounderline abstract_t">Miceli MH, Kauffman CA. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent. Clin Infect Dis 2015; 61:1558.</a></li><li><a class="nounderline abstract_t">Fu MJ, Zhou H, Ma WJ, et al. A novel case of disseminated blastomycosis in China. Chin Med J (Engl) 2019; 132:3006.</a></li><li><a class="nounderline abstract_t">Scolarici MJ, King C, Sterkel A, et al. The Role of Isavuconazonium Sulphate for the Treatment of Blastomycosis: A Case Series and Antifungal Susceptibility. Open Forum Infect Dis 2022; 9:ofac220.</a></li><li><a class="nounderline abstract_t">Sugar AM, Liu XP. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 1996; 40:1314.</a></li><li class="breakAll">US Food and Drug Administration. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-limits-usage-nizoral-ketoconazole-oral-tablets-due-potentially (Accessed on March 02, 2022).</li><li><a class="nounderline abstract_t">Treatment of blastomycosis and histoplasmosis with ketoconazole. Results of a prospective randomized clinical trial. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Ann Intern Med 1985; 103:861.</a></li><li><a class="nounderline abstract_t">Bradsher RW, Rice DC, Abernathy RS. Ketoconazole therapy for endemic blastomycosis. Ann Intern Med 1985; 103:872.</a></li><li><a class="nounderline abstract_t">Bariola JR, Perry P, Pappas PG, et al. Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern era. Clin Infect Dis 2010; 50:797.</a></li><li><a class="nounderline abstract_t">Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000; 182:274.</a></li><li><a class="nounderline abstract_t">Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003; 37:728.</a></li><li><a class="nounderline abstract_t">Li RK, Ciblak MA, Nordoff N, et al. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother 2000; 44:1734.</a></li><li><a class="nounderline abstract_t">Sugar AM, Liu XP. Efficacy of voriconazole in treatment of murine pulmonary blastomycosis. Antimicrob Agents Chemother 2001; 45:601.</a></li><li><a class="nounderline abstract_t">Bakleh M, Aksamit AJ, Tleyjeh IM, Marshall WF. Successful treatment of cerebral blastomycosis with voriconazole. Clin Infect Dis 2005; 40:e69.</a></li><li><a class="nounderline abstract_t">Borgia SM, Fuller JD, Sarabia A, El-Helou P. Cerebral blastomycosis: a case series incorporating voriconazole in the treatment regimen. Med Mycol 2006; 44:659.</a></li><li><a class="nounderline abstract_t">Harley WB, Lomis M, Haas DW. Marked polymorphonuclear pleocytosis due to blastomycotic meningitis: case report and review. Clin Infect Dis 1994; 18:816.</a></li><li><a class="nounderline abstract_t">Szeder V, Ortega-Gutierrez S, Frank M, Jaradeh SS. CNS blastomycosis in a young man working in fields after Hurricane Katrina. Neurology 2007; 68:1746.</a></li><li><a class="nounderline abstract_t">Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994; 330:263.</a></li><li><a class="nounderline abstract_t">Taillan B, Ferrari E, Cosnefroy JY, et al. Favourable outcome of blastomycosis of the brain stem with fluconazole and flucytosine treatment. Ann Med 1992; 24:71.</a></li><li><a class="nounderline abstract_t">Pearson GJ, Chin TW, Fong IW. Case report: treatment of blastomycosis with fluconazole. Am J Med Sci 1992; 303:313.</a></li><li><a class="nounderline abstract_t">Pappas PG, Bradsher RW, Chapman SW, et al. Treatment of blastomycosis with fluconazole: a pilot study. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1995; 20:267.</a></li><li><a class="nounderline abstract_t">Pappas PG, Bradsher RW, Kauffman CA, et al. Treatment of blastomycosis with higher doses of fluconazole. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1997; 25:200.</a></li><li><a class="nounderline abstract_t">Pappas PG, Pottage JC, Powderly WG, et al. Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1992; 116:847.</a></li><li><a class="nounderline abstract_t">Pappas PG, Threlkeld MG, Bedsole GD, et al. Blastomycosis in immunocompromised patients. Medicine (Baltimore) 1993; 72:311.</a></li><li><a class="nounderline abstract_t">Greene NB, Baughman RP, Kim CK, Roselle GA. Failure of ketoconazole in an immunosuppressed patient with pulmonary blastomycosis. Chest 1985; 88:640.</a></li><li><a class="nounderline abstract_t">Serody JS, Mill MR, Detterbeck FC, et al. Blastomycosis in transplant recipients: report of a case and review. Clin Infect Dis 1993; 16:54.</a></li><li><a class="nounderline abstract_t">Recht LD, Davies SF, Eckman MR, Sarosi GA. Blastomycosis in immunosuppressed patients. Am Rev Respir Dis 1982; 125:359.</a></li><li><a class="nounderline abstract_t">Butka BJ, Bennett SR, Johnson AC. Disseminated inoculation blastomycosis in a renal transplant recipient. Am Rev Respir Dis 1984; 130:1180.</a></li><li><a class="nounderline abstract_t">Linden P, Williams P, Chan KM. Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Clin Transplant 2000; 14:329.</a></li><li><a class="nounderline abstract_t">Freifeld A, Proia L, Andes D, et al. Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother 2009; 53:1648.</a></li><li><a class="nounderline abstract_t">Schutze GE, Hickerson SL, Fortin EM, et al. Blastomycosis in children. Clin Infect Dis 1996; 22:496.</a></li><li><a class="nounderline abstract_t">Morris SK, Brophy J, Richardson SE, et al. Blastomycosis in Ontario, 1994-2003. Emerg Infect Dis 2006; 12:274.</a></li><li><a class="nounderline abstract_t">Firkus D, Abu Saleh OM, Enzler MJ, et al. Does metabolite matter? Defining target itraconazole and hydroxy-itraconazole serum concentrations for blastomycosis. Mycoses 2023; 66:412.</a></li><li><a class="nounderline abstract_t">Tarr M, Marcinak J, Mongkolrattanothai K, et al. Blastomyces antigen detection for monitoring progression of blastomycosis in a pregnant adolescent. Infect Dis Obstet Gynecol 2007; 2007:89059.</a></li><li><a class="nounderline abstract_t">Mongkolrattanothai K, Peev M, Wheat LJ, Marcinak J. Urine antigen detection of blastomycosis in pediatric patients. Pediatr Infect Dis J 2006; 25:1076.</a></li><li><a class="nounderline abstract_t">Johnson MD, Perfect JR. Fungal Infections of the Bones and Joints. Curr Infect Dis Rep 2001; 3:450.</a></li><li><a class="nounderline abstract_t">Goldman M, Zackin R, Fichtenbaum CJ, et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis 2004; 38:1485.</a></li></ol></div><div id="topicVersionRevision">Topic 2463 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18462107" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21193785" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34364529" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3685662" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Self-limited blastomycosis: a report of 39 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9738049" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9087508" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29084748" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Antifungal Susceptibility of Emerging Dimorphic Pathogens in the Family Ajellomycetaceae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5787603" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A decade of experience with blastomycosis and its treatment with amphotericin B. A National Communicable Disease Center Cooperative Mycoses Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8722836" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Histoplasmosis and blastomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9313293" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Endemic blastomycosis in Mississippi: epidemiological and clinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5985246" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Amphotericin therapy of North American blastomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1759840" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11372815" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Amphotericin B lipid complex for the treatment of recurrent blastomycosis of the brain in a patient previously treated with itraconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15809926" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16567998" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Recurrent central nervous system blastomycosis in an immunocompetent child treated successfully with sequential liposomal amphotericin B and voriconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10880319" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Recurrent blastomycosis of the central nervous system: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8413389" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Overwhelming pulmonary blastomycosis associated with the adult respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11172200" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Acute respiratory distress syndrome and blastomycosis: presentation of nine cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574291" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Corticosteroids for blastomycosis-induced ARDS: a report of two patients and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27149459" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Management and Outcomes of Acute Respiratory Distress Syndrome Caused by Blastomycosis: A Retrospective Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31742741" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Altered Pharmacokinetics and Dosing of Liposomal Amphotericin B and Isavuconazole during Extracorporeal Membrane Oxygenation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31253662" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Treatment of pulmonary blastomycosis with high-dose liposomal amphotericin B in a patient receiving extracorporeal membrane oxygenation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30994894" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Apparent interference with extracorporeal membrane oxygenation by liposomal amphotericin B in a patient with disseminated blastomycosis receiving continuous renal replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32457106" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Open-Label Crossover Oral Bioequivalence Pharmacokinetics Comparison for a 3-Day Loading Dose Regimen and 15-Day Steady-State Administration of SUBA-Itraconazole and Conventional Itraconazole Capsules in Healthy Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1332471" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1314106" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Blastomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1314106" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Blastomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22564845" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Successful use of posaconazole for treatment of blastomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26179012" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31809321" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A novel case of disseminated blastomycosis in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35821730" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The Role of Isavuconazonium Sulphate for the Treatment of Blastomycosis: A Case Series and Antifungal Susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8723494" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8723494" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2865921" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Treatment of blastomycosis and histoplasmosis with ketoconazole. Results of a prospective randomized clinical trial. National Institute of Allergy and Infectious Diseases Mycoses Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4062088" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Ketoconazole therapy for endemic blastomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20166817" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10882607" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12942409" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10817743" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11158762" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Efficacy of voriconazole in treatment of murine pulmonary blastomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15825017" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Successful treatment of cerebral blastomycosis with voriconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17071562" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cerebral blastomycosis: a case series incorporating voriconazole in the treatment regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8075280" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Marked polymorphonuclear pleocytosis due to blastomycotic meningitis: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17502562" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : CNS blastomycosis in a young man working in fields after Hurricane Katrina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8272088" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Oral azole drugs as systemic antifungal therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1575964" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Favourable outcome of blastomycosis of the brain stem with fluconazole and flucytosine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1580320" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Case report: treatment of blastomycosis with fluconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7742428" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Treatment of blastomycosis with fluconazole: a pilot study. The National Institute of Allergy and Infectious Diseases Mycoses Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9332510" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Treatment of blastomycosis with higher doses of fluconazole. The National Institute of Allergy and Infectious Diseases Mycoses Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1567099" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Blastomycosis in patients with the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8412644" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Blastomycosis in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3899536" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Failure of ketoconazole in an immunosuppressed patient with pulmonary blastomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8448319" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Blastomycosis in transplant recipients: report of a case and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6950684" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Blastomycosis in immunosuppressed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6391311" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Disseminated inoculation blastomycosis in a renal transplant recipient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10945204" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19139290" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Voriconazole use for endemic fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8852969" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Blastomycosis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16494754" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Blastomycosis in Ontario, 1994-2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36648362" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Does metabolite matter? Defining target itraconazole and hydroxy-itraconazole serum concentrations for blastomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17641724" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Blastomyces antigen detection for monitoring progression of blastomycosis in a pregnant adolescent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17072135" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Urine antigen detection of blastomycosis in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11559466" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Fungal Infections of the Bones and Joints.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15156489" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
